AT&T leverages the cloud to encourage development of connected apps, a new asthma device will leverage Qualcomm's 2net hub, and a microchip for drug delivery will be put to the test in a clinical trial.
AT&T has launched a beta version of the AT&T Developer Center ForHealth, a cloud-based platform designed to help mobile health app developers create integrated applications. Eventually, AT&T hopes, the platform also will connect these apps to the information systems of healthcare organizations and insurance companies.
The deal will enable users of iSonea’s asthma monitoring devices to “automatically and securely link” asthma symptom data via Qualcomm’s 2net platform to a cloud-based portal that physicians and caregivers can access. iSonea will leverage Qualcomm Life’s 2net Hub, a plug-and-play connectivity gateway.
The MyTelcare Diabetes Pal, now available via the Apple App Store, allows patients and caregivers to use their iPhone, iPod Touch and/or iPad to visualize every glucose reading sent by the Telcare BGM (blood-glucose meter) while tracking medication, nutrition, activities and notes. What's more, the app also enables patients who don’t have the Telcare BGM to manually enter their blood-glucose data and track it over time.
Drug Store News
The clinical trial, composed of a group of women with osteoporosis in Denmark, is the first to test a wirelessly controlled microchip that can release drugs into the body at any time instead of using daily injection pens, according to a study in today’s Science Translational Medicine.
Mass High Tech
Dr. Michael Artman, the chief pediatrician at Children's Mercy Hospital in Kansas City, Mo., and a neonatal cardiologist not connected to the Stanford operation, described the surgery as an impressive accomplishment that could encourage other children's hospitals to undertake similar efforts.